Institute of Biotechnology, Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78245, USA.
Trends Biotechnol. 2010 Sep;28(9):461-7. doi: 10.1016/j.tibtech.2010.06.003. Epub 2010 Jul 14.
The ubiquitin-proteasome system handles the majority of controlled proteolysis in eukaryotes. Defects in the ubiquitin-proteasome system have been implicated in diseases ranging from cancers to neurodegenerative disorders. However, the precise role of ubiquitin-proteasome-mediated degradation in health and disease is far from clear. A major challenge is to link specific substrates directly to a particular degradation pathway. Here, we review genome-wide approaches that have been developed in recent years to comprehensively identify ubiquitylated substrates of a particular pathway. Components of the ubiquitin-proteasome system are attractive drug targets, as illustrated by the efficacy of some proteasome inhibitors in the treatment of multiple myeloma. Information that has emerged from these studies could reveal novel drug targets and strategies for treating human diseases.
泛素-蛋白酶体系统处理真核生物中大多数的受控蛋白水解。泛素-蛋白酶体系统的缺陷与从癌症到神经退行性疾病等各种疾病有关。然而,泛素-蛋白酶体介导的降解在健康和疾病中的精确作用还远不清楚。一个主要的挑战是将特定的底物直接与特定的降解途径联系起来。在这里,我们回顾了近年来开发的全基因组方法,这些方法可以全面鉴定特定途径的泛素化底物。泛素-蛋白酶体系统的组成部分是有吸引力的药物靶点,一些蛋白酶体抑制剂在多发性骨髓瘤的治疗中的疗效就证明了这一点。这些研究中出现的信息可以揭示治疗人类疾病的新的药物靶点和策略。